Drug-resistant Streptococcus pneumoniae in community-acquired pneumonia

Current Infectious Disease Reports

Volumn 5, Issue 3, 2003, Pages 230-237

  Henry, Michael ^b   Leaf, Howard L ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; GATIFLOXACIN; KETOLIDE; LEVOFLOXACIN; LINCOSAMIDE; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; PNEUMOCOCCUS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOGRAMIN; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; CLINICAL PRACTICE; COMMUNITY ACQUIRED PNEUMONIA; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CHOICE; DRUG EFFICACY; HUMAN; MEDICAL SOCIETY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PENICILLIN RESISTANCE; PRACTICE GUIDELINE; PREVALENCE; REVIEW; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; UNITED STATES;

EID: 0346464576     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-003-0078-7     Document Type: Review

References (53)

1. Feikin DR, Schuchat A, Kolczak M, et al.: Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000, 90:223-229.
2. Schuchat A, Robinson K, Wenger JD, et al.: Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med 1997, 337:970-976.
3. Taylor SN, Sanders CV: Unusual manifestations of invasive pneumococcal infection. Am J Med 1999, 26;107:12S-27S.
4. Hansman D, Bullen MM: A resistant pneumococcus. Lancet 1967, 2:264-265.
5. Campbell GD Jr, Silberman R: Drug-resistant Streptococcus pneumoniae. Clin Infect Dis 1998, 26:1188-1195.
6. Breiman RF, Butler JC, Tenover FC, et al.: Emergence of drug-resistant pneumococcal infections in the United States. JAMA 1994, 271:1831-1835.
7. Hofmann J, Cetron MS, Farley MM, et al.: The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995, 333:481-486.
8. Corso A, Severina EP, Petruk VF, et al.: Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates causing respiratory disease in the United States. Microb Drug Resist 1998, 4:325-337.
9. Doern GV, Brueggemann AB, Blocker M, et al.: Clonal relationships among high-level penicillin-resistant Streptococcus pneumoniae in the United States. Clin Infect Dis 1998, 27: 57-761.
10. Sá-Leão R, Tomasz A, Sanches IS, et al.: Carriage of internationally spread clones of Streptococcus pneumoniae with unusual drug resistance patterns in children attending day care centers in Lisbon, Portugal. J Infect Dis 2000, 182: 153-1160.
11. Jorgensen JH, Doern GV, Maher LA, et al.: Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 1999, 34: 075-2080.
12. Whitney CG, Farley MM, Hadler J, et al.: Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000, 343:1917-1924.
13. Thornsberry C, Sahm DF, Kelly LJ, et al.: Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. Clin Infect Dis 2002, 34(Suppl 1): 4-S16.
14. Spika JS, Facklam RR, Plikaytis BD, Oxtoby MJ: Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. The Pneumococcal Surveillance Working Group. J Infect Dis 1991, 163:1273-1278.
15. Doern GV, Pfaller MA, Kugler K, et al.: Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 Results from the SENTRY Clin Infect Dis 1998, 27:764-770.
16. Hyde TB, Gay K, Stephens DS, et al.: Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 2001, 286:1857-1862.
17. Appelbaum PC: Resistance among Streptococcus pneumoniae: Implications for drug selection. Clin Infect Dis 2002, 34: 613-1620.
18. Sahm DF, Peterson DE, Critchley IA, Thornsberry C: Analysis of ciprofloxacin activity against Streptococcus pneumoniae after 10 years of use in the United States. Antimicrob Agents Chemother 2000, 44:2521-2524.
19. Brueggemann AB, Coffman SL, Rhomberg P, et al.: Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob Agents Chemother 2002, 46: 80-688.
20. Chen DK, McGeer A, de Azavedo JC, Low DE: Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 1999, 341:233-239.
21. Linares J, de la Campa AG, Pallares R: Fluoroquinolone resistance in Streptococcus pneumoniae. N Engl J Med 1999, 341:1546-1547.
22. Clavo-Sanchez AJ, Giron-Gonzalez JA, Lopez-Prieto D, et al.: Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study. Clin Infect Dis 1997, 24:1052-1059.
23. Ewig S, Ruiz M, Torres A, et al.: Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am J Respir Crit Care Med 1999, 159:1835-1842.
24. Deeks SL, Palacio R, Ruvinsky R, et al.: Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pnuemoniae. Pediatrics 1999, 103:409-413.
25. Kellner JD, McGeer A, Cetron MS, et al.: The use of Streptococcus pneumoniae nasopharyngeal isolates from healthy children to predict features of invasive disease. Pediatr Infect Dis J 1998, 17:279-286.
26. Kellner JD, Ford-Jones EL: Streptococcus pneumoniae carriage in children attending 59 Canadian child care centers. Toronto Child Care Centre Study Group. Arch Pediatr Adolesc Med 1999, 153:495-502.
27. Chiu SS, Ho PL, Chow FK, et al.: Nasopharyngeal carriage of antimicrobial-resistant Streptococcus pneumoniae among young children attending 79 kindergartens and day care centers in Hong Kong. Antimicrob Agents Chemother 2001, 45:2765-2770.
28. NCCLS: Performance Standards for Antimicrobial Susceptibility Testing: Twelfth Informational Supplement M100-S12. Wayne, Pa: NCCLS.
29. Jorgensen JH, Weigel LM, Ferraro MJ, et al.: Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci. Antimicrob Agents Chemother 1999, 43:329-334.
30. McCullers JA, English BK, Novak R: Isolation and characterization of vancomycin-toterant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis J Infect Dis 2000, 81:369-373.
31. Henriques Normark B, Novak R, et al.: Clinical isolates of Streptococcus pneumoniae that exhibit tolerance of vancomycin Clin Infect Dis 2001, 32:552-558.
32. Austrian R, Gold J: Pneumococcal bacteremia with special reference to bactermic pneumococcal pneumonia. Ann Intern Med 1964, 60:759-776.
33. Bishai W: The in vivo-in vitro paradox in pneumococcal respiratory tract infections. J Antimicrob Chemother 2002, 49:433-436.
34. Friedland IR, McCracken GH Jr: Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994, 331:377-382.
35. Metlay JP, Hofmann J, Cetron MS, et al.: Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000, 30: 20-528.
36. Winston LG, Perlman JL, Rose DA, Gerberding JL: Penicillin-nonsusceptible Streptococcus pneumoniae at San Francisco General Hospital. Clin Infect Dis 1999, 29:580-585.
37. Pallares R, Linares J, Vadillo M, et al.: Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995, 333: 74-480.
38. Plouffe JF, Breiman RF, Facklam RR: Bacteremia with Streptococcus pneumoniae. Implications for therapy and prevention. Franklin County Pneumonia Study Group. JAMA 1996, 275: 94-198.
39. File TM Jr: Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of beta-lactam-resistant Streptococcus pneumoniae. Clin Infect Dis 2002, 34(Suppl 1):S17-S26.
40. Heffelfinger JD, Dowell SF, Jorgensen JH, et al.: Management of community-acquired pneumonia in the era of pneumococcal resistance: a report the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000, 160: 399-1408.
41. Pallares R, Capdevila O, Linares J, et al.: The effect of cephalosporin resistance on mortality in adult patients with nonmeningeal systemic pneumococcal infections. Am J Med 2002, 113:120-126.
42. Lonks JR, Garau J, Gomez L, et al.: Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002, 35:556-564.
43. Lynch III JP, Martinez, F: Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia. Clin Infect Dis 2002, 34(Suppl 1):S27-S46.
44. Urban C, Rahman N, Zhao X, et al.: Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. J Infect Dis 2001, 184:794-798.
45. Ross JJ, Worthington MG, Gorbach SL, et al.: Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia N Engl J Med 2002, 347:65-67.
46. Bartlett JG, Dowell SF, Mandell LA, et al.: Practice guidelines for the management of community-acquired pneumonia in adults. infectious Diseases Society ofAmerica. Clin Infect Dis 2000, 31:347-382.
47. Niederman MS, Mandell LA, Anzueto A, et al.: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001, 163:1730-1754.
48. Davies TA, Dewasse BE, Jacobs MR, Appelbaum PC: In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae. Antimicrob Agents Chemother 2000, 44:414-417.
49. Klugman KP: Antibiotic selection of multiply resistant pneumococci. Clin Infect Dis 2001, 33:489-489.
50. Song JH, Lee NY, Ichiyama S, et al.: Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study. Clin Infect Dis 1999, 28:1206-1211.
51. Huebner RE, Wasas AD, Klugman KP: Trends in antimicrobial resistance and serotype distribution of blood and cerebrospinal fluid isolates of Streptococcus pneumoniae in South Africa, 1991-1998. Int J Infect Dis 2000, 4:214-218.
52. Turnidge JD, Bell JM, Collignon PJ: Rapidly emerging antimicrobial resistances in Streptococcus pneumoniae in Australia. Pneumococcal Study Group. Med J Aust 1999, 170:152-155.
53. Ho PL, Yung RW, Tsang DN, et al.: Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J Antimicrob Chemother 2001, 48:659-665.